Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer

被引:1
|
作者
Alshamsan, Bader [1 ,2 ]
Alshibany, Aisha [1 ]
Elshenawy, Mahmoud A. [1 ,3 ]
Badran, Ahmed [1 ,4 ]
Elhassan, Tusneem [1 ]
Ajarim, Dahish [1 ]
Alsayed, Adher [1 ]
Suleman, Kausar [1 ]
Al-Tweigeri, Taher [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Med Oncol, Riyadh, Saudi Arabia
[2] Qassim Univ, Dept Med, Coll Med, Qasim, Saudi Arabia
[3] Menoufia Univ, Clin Oncol, Fac Med, Shibin Al Kawm, Egypt
[4] Ain Shams Univ Hosp, Dept Clin Oncol, Cairo, Egypt
来源
关键词
neutrophil-to-lymphocyte ratio; Oncotype Dx recurrence score; early-stage breast cancer; hormonal receptor-positive; human epidermal growth factor receptor 2-negative; node-negative breast cancer; GENE-EXPRESSION; TUMOR-MARKER; CHEMOTHERAPY; SURVIVAL; BENEFIT; RISK; PREDICTION; PROGNOSIS; SUBTYPE; WOMEN;
D O I
10.2147/CMAR.S343549
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The correlation between the preoperative neutrophil-to-lymphocyte ratio (NLR) and Oncotype DX (R) (ODX) recurrence score (RS) has not yet been established. We aimed to investigate the association between NLR and ODX RS in patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer (BC). Patients and Methods: This retrospective study included consecutive patients with HR +/HER2-, node-negative primary BC who underwent surgical tumor resection from 2011 to 2019. Receiver operating characteristic curve analysis was used to obtain an optimal NLR cutoff value. Logistic regression analyses were used to estimate associations between various parameters and ODX RS. Furthermore, the factors significantly associated with the ODX RS in multivariable analysis were incorporated in a separate model and estimated using logistic regression. Results: A total of 160 patients were enrolled. The optimal preoperative NLR cutoff was 2.15. Multivariable analysis revealed that NLR and tumor grade (G1/G2 vs G3) were independent predictive factors of high RS cutoff (>= 26). Moreover, including the two variables yielded a stronger association; patients with low NLR and low-grade tumors were unlikely to have high RS (>= 26; odds ratio [OR] = 0.03, 95% confidence interval [CI]: 0.006-0.154; p < 0.001). Conversely, the presence of any of the following factors made patients unlikely to have low RS (<16; OR = 0.34, 95% CI: 0.16-0.73; p = 0.006): high NLR, high grade, or high Ki-67 levels (>20). Conclusion: NLR is a promising independent predictor of RS. Furthermore, in addition to tumor grade and Ki-67 level, they together are also a potential indicator of high and low RS. However, further studies are required to validate this hypothesis.
引用
收藏
页码:9411 / 9420
页数:10
相关论文
共 50 条
  • [1] Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score
    Meisel, Jane
    Zhang, Chao
    Neely, Cameron
    Menduza, Pia
    You, Shuo
    Han, Tatiana
    Liu, Yuan
    Sahin, Aysegul A.
    O'Regan, Ruth
    Li, Xiaoxian
    [J]. CLINICAL BREAST CANCER, 2018, 18 (05) : 347 - 352
  • [2] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [3] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Lee, Su Hyun
    Ha, Seunggyun
    An, Hyun Joon
    Lee, Jae Sung
    Han, Wonshik
    Im, Seock-Ah
    Ryu, Han Suk
    Kim, Won Hwa
    Chang, Jung Min
    Cho, Nariya
    Moon, Woo Kyung
    Cheon, Gi Jeong
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) : 1574 - 1584
  • [4] Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
    Su Hyun Lee
    Seunggyun Ha
    Hyun Joon An
    Jae Sung Lee
    Wonshik Han
    Seock-Ah Im
    Han Suk Ryu
    Won Hwa Kim
    Jung Min Chang
    Nariya Cho
    Woo Kyung Moon
    Gi Jeong Cheon
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 1574 - 1584
  • [5] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
    Logan, Suzanna J.
    Zhang, Chao
    Liu, Yuan
    Siddiqui, Momin T.
    Cohen, Cynthia
    Li, Xiaoxian
    [J]. LABORATORY INVESTIGATION, 2017, 97 : 56A - 57A
  • [6] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
    Logan, Suzanna J.
    Zhang, Chao
    Liu, Yuan
    Siddiqui, Momin T.
    Cohen, Cynthia
    Li, Xiaoxian
    [J]. MODERN PATHOLOGY, 2017, 30 : 56A - 57A
  • [7] Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
    Mittendorf, Elizabeth A.
    King, Tari A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (05) : 1173 - 1175
  • [8] Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come
    Elizabeth A. Mittendorf
    Tari A. King
    [J]. Annals of Surgical Oncology, 2019, 26 : 1173 - 1175
  • [9] Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
    Kwon, Mi Jeong
    Lee, Jeong Eon
    Jeong, Joon
    Woo, Sang Uk
    Han, Jinil
    Kang, Byeong-il
    Kim, Jee-Eun
    Moon, Youngho
    Lee, Sae Byul
    Lee, Seonghoon
    Choi, Yoon-La
    Kwon, Youngmi
    Song, Kyoung
    Gong, Gyungyub
    Shin, Young Kee
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [10] Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
    Nagaraj, Gayathri
    Ma, Cynthia X.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (03): : 246 - 251